Background
Acquired copy-neutral loss of heterozygosity (CN-LOH) has been described in myeloid malignant progression with an otherwise normal karyotype.
Case Report
A 65 year old woman with MPL-mutated essential thrombocythemia (ET) and progression to myelofibrosis was noted upon routine pre-transplant testing to have mixed field reactivity with anti-D and a historical discrepancy in RhD type. The patient had never received transfusions or transplantation.
Results
Gel immunoagglutination revealed group A red blood cells (RBCs) and a mixed-field reaction for the RhD phenotype, with a predominant RhD-negative population and a small subset of circulating RBCs carrying the RhD antigen. Subsequent genomic microarray SNP profiling revealed CN-LOH of chromosome 1 p36.33-p34.2, a known molecular mechanism underlying fibrotic progression of MPL-mutated ET. The chromosomal region affected by this CN-LOH encompassed the RHD, RHCE, and MPL genes. We propose a model of chronological molecular events that is supported by RHD zygosity assays in peripheral lymphoid and myeloid-derived cells.
Conclusion
CN-LOH events that lead to clonal selection and myeloid malignant progression may also affect the expression of adjacent unrelated genes, including those encoding for blood group antigens. Detection of mixed-field reactions and investigation of discrepant blood typing results is important for proper transfusion support of these patients and can provide a useful surrogate marker of myeloproliferative disease progression.